AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20090326 — intervention group
Group type: COMPARATOR
Intervention: Control sugar (65% sucrose + 33% glucose syrup)
Number of subjects: 24
Study 20090326 — intervention group
Group type: COMPARATOR
Intervention: Control sugar-free
Number of subjects: 24
Study 17367769 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 S(*)2 allele in female smokers
Number of subjects: 673
Study 17367769 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 S(*)2 allele in female nonsmokers
Number of subjects: 673
Study 17367769 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 polymorphisms in male carriers of less common alleles (‐482T and ‐455C)
Number of subjects: 673
Study 17367769 — intervention group
Group type: COMPARATOR
Intervention: APOC3 S(*)1S(*)1 homozygotes with APOE(*)3/3 genotype
Number of subjects: 673
Study 15741189 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in patient-centred communication for specialists in gastroenterology
Number of subjects: 700
Study 12006521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pac/FAC (4 cycles of paclitaxel followed by 4 cycles of FAC)
Number of subjects: 524
Study 12006521 — intervention group
Group type: COMPARATOR
Intervention: FAC (8 cycles of FAC)
Number of subjects: 524
Study 12006521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pac/FAC
Number of subjects: 524
Study 12006521 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 524
Study 9616321 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 3540
Study 9616321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 3540
Study 7667456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral stress-management program (20 biweekly sessions of progressive muscle relaxation, electromyograph biofeedback-assisted relaxation training, meditation, and hypnosis)
Number of subjects: 10
Study 7667456 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 10
Study 2495891 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel
Number of subjects: 1800
Study 2495891 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic preparation
Number of subjects: 1800
Study 2495891 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone
Number of subjects: 1800
Study 878906 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.27 microgram X kg‐1 X min‐1
Number of subjects: 5
Study 878906 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.03, 0.06, 0.09 microgram X kg‐1 X min‐1
Number of subjects: 5
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing adiposity
Number of subjects: 401
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea drinking
Number of subjects: 401
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent watching television
Number of subjects: 401
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 401
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 401
Study 31659794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 401
Study 28139259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 units daily for 12 weeks
Number of subjects: 98
Study 28139259 — intervention group
Group type: COMPARATOR
Intervention: Observation for 12 weeks
Number of subjects: 98
Study 26083706 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week skiing intervention
Number of subjects: 0
Study 23164343 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated platelet-rich plasma (PRP) applied along the fracture line
Number of subjects: 24
Study 23164343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP applied)
Number of subjects: 24
Study 21680622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 305
Study 21680622 — intervention group
Group type: COMPARATOR
Intervention: Routine podiatry care (Control)
Number of subjects: 305
Study 19327616 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU)
Number of subjects: 400
Study 19327616 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 400
Study 16555157 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN group, n=20)
Number of subjects: 40
Study 16555157 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN group, n=20)
Number of subjects: 40
Study 15592267 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent defective healing group (17 women with sling erosion)
Number of subjects: 24
Study 15592267 — intervention group
Group type: COMPARATOR
Intervention: Single-debridement group (not specified how many)
Number of subjects: 24
Study 15592267 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 women with voiding difficulty or symptomatic vaginal prolapse)
Number of subjects: 24
Study 11742910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg/d
Number of subjects: 237
Study 11742910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg/d
Number of subjects: 237
Study 11742910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 11263281 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-penetration and oral administration of traditional Chinese decoction plus traction
Number of subjects: 91
Study 11263281 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Chinese decoction and traction
Number of subjects: 91
Study 8644682 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg Fe/d)
Number of subjects: 139
Study 8644682 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation (120 mg Fe/wk)
Number of subjects: 139
Study 8644682 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg Fe/d) in subgroup (n = 45)
Number of subjects: 139
Study 8644682 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation (120 mg Fe/wk) in subgroup (n = 54)
Number of subjects: 139
Study 8644682 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance in daily group
Number of subjects: 139
Study 8644682 — intervention group
Group type: COMPARATOR
Intervention: Compliance in weekly group
Number of subjects: 139
Study 1687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 21
Study 1687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 21
Study 1687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 21
Study 1687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 200 mg
Number of subjects: 21
Study 1687121 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (all doses)
Number of subjects: 21
Study 6347123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate with low-dose heparin sodium
Number of subjects: 181
Study 6347123 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin alone
Number of subjects: 181
Study 30772343 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of freshly collected autologous adipose tissue
Number of subjects: 21
Study 28816707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise with brace adjustment twice per week
Number of subjects: 30
Study 28816707 — intervention group
Group type: COMPARATOR
Intervention: Routine protocol (Control)
Number of subjects: 30
Study 27431233 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine (study 1)
Number of subjects: 68
Study 27431233 — intervention group
Group type: COMPARATOR
Intervention: 50 mg tribendimidine (study 2)
Number of subjects: 68
Study 27431233 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥100 mg tribendimidine
Number of subjects: 68
Study 27431233 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dADT peak concentrations
Number of subjects: 68
Study 27431233 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adADT peak concentrations
Number of subjects: 68
Study 24158761 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel daily for 6 months
Number of subjects: 0
Study 24158761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22170878 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation (cTBS) applied over the intact posterior parietal cortex (PPC) of the left hemisphere (LH) for 10 sessions over 2 weeks
Number of subjects: 10
Study 22170878 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta-burst stimulation (sham cTBS)
Number of subjects: 10
Study 22170878 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst stimulation (cTBS)
Number of subjects: 10
Study 20634030 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB)
Number of subjects: 40
Study 20634030 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural block (CEB)
Number of subjects: 40
Study 17467430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooling to 32 degrees C and rewarming to 34 degrees C)
Number of subjects: 223
Study 17467430 — intervention group
Group type: COMPARATOR
Intervention: Control group (rewarming to 37 degrees C)
Number of subjects: 223
Study 16248463 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF intranasally used in one single nasal cavity a week after ESS
Number of subjects: 10
Study 16248463 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment in the other nasal cavity)
Number of subjects: 10
Study 12092987 — intervention group
Group type: COMPARATOR
Intervention: 1% CHX gel (single professional tooth cleaning)
Number of subjects: 128
Study 12092987 — intervention group
Group type: COMPARATOR
Intervention: 1% CHX and 1% thymol dental varnish (duplicate applications)
Number of subjects: 128
Study 12092987 — intervention group
Group type: COMPARATOR
Intervention: 40% CHX varnish (single application)
Number of subjects: 128
Study 12092987 — intervention group
Group type: COMPARATOR
Intervention: 1% CHX gel (daily tooth brushing for 2 weeks)
Number of subjects: 128
Study 9846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice
Number of subjects: 15
Study 9846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato oleoresin
Number of subjects: 15
Study 9846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene beadlets
Number of subjects: 15
Study 9846845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice and lycopene beadlets
Number of subjects: 15
Study 9846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice, oleoresin, and lycopene beadlets
Number of subjects: 15
Study 8620970 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 10
Study 8620970 — intervention group
Group type: COMPARATOR
Intervention: Control (no methacholine challenge)
Number of subjects: 10
Study 2486582 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbotage with 0.5% tetracaine
Number of subjects: 80
Study 2486582 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbotage with 0.5% bupivacaine
Number of subjects: 80
Study 2486582 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine without barbotage
Number of subjects: 80
Study 2486582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with barbotage
Number of subjects: 80
Study 2486582 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine without barbotage
Number of subjects: 80
Study 31661179 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented liability to migraine
Number of subjects: 59674
Study 31661179 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 59674
Study 31661179 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 59674
Study 31250576 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 220
Study 31250576 — intervention group
Group type: COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 220
Study 28463879 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Number of subjects: 0
Study 28463879 — intervention group
Group type: COMPARATOR
Intervention: Standard of care ART initiation
Number of subjects: 0
Study 25448776 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 212
Study 23148565 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 23148565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 0
Study 22288298 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 6 g/24-hour
Number of subjects: 19
Study 22288298 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 12 g/24-hour
Number of subjects: 19
Study 22288298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19375091 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Number of subjects: 22
Study 19375091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16773028 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe sex (defined as at least 1 episode of anal sexual intercourse without a condom with a casual partner during the previous 12 months)
Number of subjects: 1117
Study 16773028 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor mental health-related quality of life (HRQL)
Number of subjects: 1117
Study 15182980 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy age and height matched)
Number of subjects: 14
Study 15182980 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with posterior pelvic pain
Number of subjects: 14
Study 11283865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN + AMA)
Number of subjects: 200
Study 11283865 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (IFN)
Number of subjects: 200
Study 9313664 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-PLA spiral stent
Number of subjects: 45
Study 9313664 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 45
Study 12959272 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24
Study 12959272 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24
Study 3102127 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen (prostaglandin synthetase inhibitor)
Number of subjects: 28
Study 3102127 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study 30261896 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 15 mg/kg
Number of subjects: 30
Study 30261896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25919120 — intervention group
Group type: EXPERIMENTAL
Intervention: IA+MF
Number of subjects: 14
Study 25919120 — intervention group
Group type: COMPARATOR
Intervention: IA alone
Number of subjects: 14
Study 25746726 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective REM sleep deprivation (awakening at each REM sleep onset)
Number of subjects: 18
Study 25746726 — intervention group
Group type: COMPARATOR
Intervention: Control group (same number of NREM sleep awakenings)
Number of subjects: 18
Study 23570596 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose triptorelin (1.875 mg each time)
Number of subjects: 186
Study 21102204 — intervention group
Group type: COMPARATOR
Intervention: Lateral-entry pinning
Number of subjects: 104
Study 21102204 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial and lateral (crossed) pinning
Number of subjects: 104
Study 21102204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 18654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder retraining
Number of subjects: 500
Study 18654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs
Number of subjects: 500
Study 18654731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bladder retraining and anticholinergic drugs
Number of subjects: 500
Study 16905197 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement schedule with increasing magnitude for consecutive abstinences
Number of subjects: 0
Study 16905197 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement schedule with reset in reinforcer magnitude for a positive drug test
Number of subjects: 0
Study 12546342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (0.68 mg), pseudoephedrine (60 mg), and acetaminophen (1,000 mg)
Number of subjects: 298
Study 12546342 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine and acetaminophen
Number of subjects: 298
Study 12546342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 10491719 — intervention group
Group type: EXPERIMENTAL
Intervention: One sample of immunological fecal occult blood test (FOBT)
Number of subjects: 332
Study 10491719 — intervention group
Group type: EXPERIMENTAL
Intervention: Three samples of immunological fecal occult blood test (FOBT)
Number of subjects: 332
Study 8894261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-5 mg/day)
Number of subjects: 27
Study 8894261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 27
Study 8894261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1797490 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gemfibrozil
Number of subjects: 14
Study 1797490 — intervention group
Group type: COMPARATOR
Intervention: Placebo gemfibrozil
Number of subjects: 14
Study 6347746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (200 mg/day)
Number of subjects: 100
Study 6347746 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone (400 mg/day)
Number of subjects: 100
Study 29673467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention (two 1-hour individualized sessions targeting CHD education and self-management skills)
Number of subjects: 121
Study 29673467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention
Number of subjects: 121
Study 29673467 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 121
Study 27645285 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERVAL trial participants (randomised)
Number of subjects: 48725
Study 27645285 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised donors
Number of subjects: 48725
Study 23406290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g amoxicillin one hour pre-operatively
Number of subjects: 55
Study 23406290 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules 1 hour pre-operatively
Number of subjects: 55
Study 23265154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHX)
Number of subjects: 42
Study 23265154 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 42
Study 19460761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra 100 mg/day + pegsunercept 800 microg/kg twice a week)
Number of subjects: 22
Study 19460761 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (anakinra 100 mg/day)
Number of subjects: 22
Study 19460761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 22
Study 18550331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (Visual Analogue Scale)
Number of subjects: 0
Study 18550331 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care arm)
Number of subjects: 0
Study 18550331 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation ratio estimation
Number of subjects: 0
Study 16826487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal skin test with heat-inactivated Lancy-Vaxina
Number of subjects: 83
Study 16826487 — intervention group
Group type: COMPARATOR
Intervention: Positive vaccinia-specific interferon-gamma-producing T cell response
Number of subjects: 83
Study 16826487 — intervention group
Group type: COMPARATOR
Intervention: Positive neutralizing antibody
Number of subjects: 83
Study 14526158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual AP points including Du 20, bilateral Li 4, Ren 3, Ren 4, Ren 6, bilateral Gb 34, bilateral Ub 23, bilateral Lp 6, auriculoacupuncture points)
Number of subjects: 57
Study 14526158 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 57
Study 14526158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (manual AP points)
Number of subjects: 57
Study 10890632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg afelimomab three times daily over 3 days
Number of subjects: 23
Study 10890632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10890632 — intervention group
Group type: EXPERIMENTAL
Intervention: Afelimomab
Number of subjects: 23
Study 8750392 — intervention group
Group type: EXPERIMENTAL
Intervention: QMR with temporal content
Number of subjects: 105
Study 8750392 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower temporal complexity)
Number of subjects: 105
Study 1574014 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 30
Study 1574014 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 30
Study 3922887 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial diet preparation 1
Number of subjects: 0
Study 3922887 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial diet preparation 2
Number of subjects: 0
Study 3922887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31273783 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 162
Study 31273783 — intervention group
Group type: COMPARATOR
Intervention: l-carnitine
Number of subjects: 162
Study 29554111 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-Centred Care Intervention Program
Number of subjects: 60